Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Fall;4(3):e120-6.
doi: 10.2500/ar.2013.4.0065.

Efficacy of mometasone furoate and fluticasone furoate on persistent allergic rhinoconjunctivitis

Affiliations

Efficacy of mometasone furoate and fluticasone furoate on persistent allergic rhinoconjunctivitis

W Hamizan Aneeza et al. Allergy Rhinol (Providence). 2013 Fall.

Abstract

Allergic rhinoconjunctivitis denotes both nasal and ocular manifestation of allergy, which may be solely treated with intranasal steroid. This study compares the efficacy of mometasone furoate nasal spray (NS) and fluticasone furoate NS in treatment of allergic rhinoconjunctivitis. The secondary objective is to study the severity of baseline ocular symptoms in allergic rhinoconjunctivitis. Seventy-eight patients with allergic rhinoconjunctivitis were assessed subjectively and objectively using twice-daily symptom scores for nasal (reflective total nasal symptom score [rTNSS] and instantaneous TNSS [iTNSS]) and ocular (reflective total ocular symptom score [rTOSS] and instantaneous TOSS [iTOSS]) symptoms, rhinoconjunctivitis quality-of-life questionnaires (RQOLQs), and acoustic rhinometry. All measurements were taken at baseline and at 4 and 8 weeks of treatment. Sixty-three patients who were randomized into the mometasone furoate group (n = 36) and the fluticasone furoate group (n = 27) completed the study. Seventy-six percent of patients had mild ocular symptoms, 20.5% had moderate symptoms, and only 2.6% had severe symptoms at baseline based on the iTOSS; 65.1% had mild nasal symptoms and 3% had severe nasal symptoms. There was significant reduction in the symptom scores after 1 week (p < 0.05). Both groups had significant improvement in RQOLQ scores after 1 month, which further improved at 2 months (p < 0.05). The nasal dimensions also improved in both groups (p < 0.05) but there was no statistically significant difference between groups. Both mometasone furoate and fluticasone furoate are effective as single-modality treatment of allergic rhinoconjunctivitis. The majority of patients manifest mild ocular symptoms that may be solely treated with intranasal steroids.

Keywords: Allergic rhinoconjunctivitis; fluticasone furoate; intranasal steroids; mometasone furoate; ocular symptoms; perennial allergic rhinitis.

PubMed Disclaimer

Conflict of interest statement

The authors have no conflicts of interest to declare pertaining to this article

Figures

Figure 1.
Figure 1.
Comparison between instantaneous total nasal symptom score (iTNSS) and instantaneous total ocular symptom score (iTOSS) after treatment with mometasone furoate nasal spray (NS) or fluticasone furoate NS. There was no statistical difference in efficacy between the two intranasal steroids.

Similar articles

Cited by

References

    1. Bousquet J, van Cauwenberge P, Khaltaev N, et al. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol 108:S147–S334, 2001 - PubMed
    1. Ng ML, Warlow RS, Chrishanthan N, et al. Preliminary criteria for the defnition of allergic rhinitis: A systematic evaluation of clinical parameters in a disease cohort (I). Clin Exp Allergy 30:1314–1331, 2000 - PubMed
    1. Canonica GW, Mullol J, Pradalier A, Didier A. Patient perceptions of allergic rhinitis and quality of life. Findings from a survey conducted in Europe and the United States. World Allergy Organization 1:138–144, 2008 - PMC - PubMed
    1. Wallace DV, Dykewicz MS, Bernstein DI, et al. The diagnosis and management of rhinitis: An updated practice parameter. J Allergy Clin Immunol 122:S1–-S84, 2008 - PubMed
    1. Brunton SA, Fromer LM. Treatment options on management of perennial allergic rhinitis with focus on intranasal corticosteroid. South Med J 100:701–708, 2007 - PubMed